#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10596	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2081	504.8	0	.	n	.	0	C326T	SNP	326	326	C	574	574	T	529	T,C	392,99	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10596	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2081	504.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1432	1432	C	597	C,A,G	586,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19688	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3652	536.9	0	.	n	.	0	T695C	SNP	695	695	T	1115	1115	C	572	C,T,A	555,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19688	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3652	536.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1757	1757	A	686	A,G	673,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19688	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3652	536.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2391	2391	C	613	C	598	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19688	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3652	536.9	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3017	3017	T	580	T,C	562,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19688	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3652	536.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2465	2465	A	599	A	592	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1422	folP	852	852	100.0	folP.l15.c4.ctg.1	1500	94.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1009	1011	AGC	139;139;141	A;G;C,A	136;136;134,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3522	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3419	102.6	1	SNP	p	S91F	0	.	.	271	273	TCC	652	654	TCC	106;106;110	T;C;C	104;103;107	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3522	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3419	102.6	1	SNP	p	D95N	0	.	.	283	285	GAC	664	666	GAC	108;109;108	G;A;C	105;105;102	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3522	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3419	102.6	1	SNP	p	D95G	0	.	.	283	285	GAC	664	666	GAC	108;109;108	G;A;C	105;105;102	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	1226	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1359	89.6	1	SNP	p	G45D	1	.	.	133	135	GAC	511	513	GAC	143;143;143	G;A;C	141;142;141	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	632	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1142	55.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3546	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2965	119.1	1	SNP	p	D86N	0	.	.	256	258	GAC	628	630	GAC	136;135;137	G;A;C	133;131;134	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3546	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2965	119.1	1	SNP	p	S87I	0	.	.	259	261	AGT	631	633	AGT	142;140;139	A;G;T	139;137;136	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3546	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2965	119.1	1	SNP	p	S87R	0	.	.	259	261	AGT	631	633	AGT	142;140;139	A;G;T	139;137;136	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3546	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2965	119.1	1	SNP	p	S87W	0	.	.	259	261	AGT	631	633	AGT	142;140;139	A;G;T	139;137;136	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3546	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2965	119.1	1	SNP	p	S88P	0	.	.	262	264	TCC	634	636	TCC	139;145;147	T;C;C	134;138;142	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2836	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2665	106.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1507	1509	GGC	133;133;133	G,A;G;C	128,1;129;128	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	2674	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2448	108.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1346	1348	GCA	161;161;163	G;C;A	156;152;159	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2674	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2448	108.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1349	1351	ATC	162;162;163	A;T;C	156;157;156	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2674	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2448	108.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1361	1363	GTG	173;171;173	G;T,G;G	167;165,1;169	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2674	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2448	108.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1361	1363	GTG	173;171;173	G;T,G;G	167;165,1;169	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2674	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2448	108.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1865	1867	ACC	102;103;102	A;C;C	92;100;98	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2674	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2448	108.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1919	1921	GCG	85;85;86	G;C,G;G	80;76,2;84	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2674	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2448	108.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1919	1921	GCG	85;85;86	G;C,G;G	80;76,2;84	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2674	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2448	108.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2042	2044	GGC	95;92;92	G;G,A;C	90;86,1;87	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2674	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2448	108.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2051	2053	GGC	87;86;86	G;G;C	82;86;83	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2674	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2448	108.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2069	2071	CCG	69;69;69	C,G;C;G,C	63,1;63;57,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	4014	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3166	126.2	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1686	1688	CTG	153;153;151	C,A;T;G	144,1;146;142	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1880	porA	1146	1146	99.83	porA.l6.c30.ctg.1	1769	104.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	572	572	C	136	C	124	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	234	porB1a	984	275	91.04	porB1a.l6.c30.ctg.2	419	17.7	0	.	p	.	0	H217N	NONSYN	649	651	CAT	169	171	AAT	9;9;10	A;A;T	9;9;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	234	porB1a	984	275	91.04	porB1a.l6.c30.ctg.2	419	17.7	0	.	p	.	0	D218N	NONSYN	652	654	GAT	172	174	AAT	10;11;11	A;A;T	10;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	234	porB1a	984	275	91.04	porB1a.l6.c30.ctg.2	419	17.7	0	.	p	.	0	A222V	NONSYN	664	666	GCT	184	186	GTT	10;9;9	G;T;T	10;9;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	234	porB1a	984	275	91.04	porB1a.l6.c30.ctg.2	419	17.7	0	.	p	.	0	V226A	NONSYN	676	678	GTA	196	198	GCA	9;9;10	G;C;A	9;9;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	234	porB1a	984	275	91.04	porB1a.l6.c30.ctg.2	419	17.7	0	.	p	.	0	.	MULTIPLE	700	702	ACT	219	221	GTA	11;11;11	G;T;A	11;11;11	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	234	porB1a	984	275	91.04	porB1a.l6.c30.ctg.2	419	17.7	0	.	p	.	0	D238fs	FSHIFT	712	712	G	231	231	G	17	G	17	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	G38E	NONSYN	112	114	GGA	412	414	GAA	163;163;162	G;A;A	162;161;161	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	S46G	NONSYN	136	138	AGC	436	438	GGC	150;146;146	G;G;C	149;146;144	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	E48G	NONSYN	142	144	GAA	442	444	GGA	151;148;148	G;G;A	151;146;145	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	T87A	NONSYN	259	261	ACT	559	561	GCT	151;152;154	G,A;C;T	147,2;146;149	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	T89S	NONSYN	265	267	ACC	565	567	AGC	150;146;145	A;G;C	144;142;137	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	.	MULTIPLE	358	359	AA	657	658	CG	138;142	C,A;G,A	133,1;135,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	.	MULTIPLE	361	362	GA	660	662	CAG	142;141;139	C;A;G	137;139;137	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	N122K	NONSYN	364	366	AAC	664	666	AAA	140;140;141	A;A;A	137;139;137	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	K143E	NONSYN	427	429	AAA	727	729	GAA	151;147;148	G,A,C;A;A	145,1,1;143;141	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	V151A	NONSYN	451	453	GTA	751	753	GCA	152;154;154	G;C,T;A	146;147,1;145	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	859	861	CGA	155;152;148	C;G;A	149;146;144	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	A215T	NONSYN	643	645	GCT	943	945	ACT	147;148;148	A,G;C,A;T	142,1;144,1;141	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	946	948	CAT	148;150;149	C;A;T	147;146;145	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	I218M	NONSYN	652	654	ATA	952	954	ATG	150;151;149	A;T;G	148;148;146	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1066	1068	GCA	131;132;130	G;C;A	130;129;128	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1069	1071	ACG	129;131;132	A;C;G	126;129;129	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	S258R	NONSYN	772	774	AGT	1072	1074	AGG	132;130;129	A;G;G	130;128;127	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1075	1077	GTT	127;129;128	G;T;T	126;125;128	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1135	1137	GTA	144;142;140	G;T;A	139;137;136	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1174	1176	ACT	151;152;154	A;C;T	143;148;152	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1180	1182	GAT	156;157;159	G;A;T	147;153;157	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	S295D	NONSYN	883	885	AGT	1183	1185	GAT	161;158;159	G;A;T	155;155;157	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1189	1191	AAC	159;158;157	A;A;C	155;153;155	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1192	1194	CAC	155;156;157	C;A;C	151;153;153	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	1	SNP	p	G120K	1	.	.	358	360	AAG	657	659	CGG	138;142;138	C,A;G,A;G	133,1;135,1;134	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	1	SNP	p	D121N	0	.	.	361	363	GAC	660	663	CGC	142;139;140	C;G;C	137;137;137	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	1898	porB1b	1047	1047	96.56	porB1b.l15.c17.ctg.1	1487	126.7	1	SNP	p	A121D	1	.	.	361	363	GAC	660	663	CGC	142;139;140	C;G;C	137;137;137	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	7020	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4725	147.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1883	1885	AAT	164;165;164	A;A;T	163;164;162	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	858	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1104	77.4	1	SNP	p	V57M	1	.	.	169	171	ATG	540	542	ATG	188;189;190	A;T;G	187;185;188	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
